Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Innovent and IASO Report Positive Data from BCMA CAR-T Trial

publication date: Jun 8, 2021

Innovent Bio of Suzhou and Nanjing IASO Bio posted positive data from a Phase I trial of their CAR-T therapy in multiple myeloma patients. CT103A, a BCMA CAR-T candidate, produced a 97% overall response rate (ORR) in 35 patients with relapsed/refractory multiple myeloma. Of these, 20 patients (57%) experienced a complete response. The two companies have already started a pivotal China Phase II trial in the same population. In February 2021, CT103A was granted Breakthrough Therapy Designation in China. More details....

Stock Symbol: (HK: 01801)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.